Search

Background: The mandibular third molar is the most frequently impacted tooth. An impacted mandibular third molar (IMTM) can have negative consequences on the adjacent mandibular second molar (MSM), such as bone loss. An IMTM can be identified using orthopantomography (OPG). Our objective is to compare changes in bone level distal to the mandibular second molar (MSM) in patients with an extracted IMTM versus non-extracted IMTM using OPG. Methods: In this retrospective case–control study, 160 orthopantomograms (OPGs) of 80 patients who attended Dental Hospital of the University of Barcelona (HOUB) were randomly selected. Participants were stratified into a study group and control group. Results: Males and females experienced bone gain in the study group and bone loss in the control group. However, the difference in bone-level change was not statistically significant regarding gender in the study group. Within the study group, the age group of 29–39 years demonstrated significant (p-value = 0.042) bone gain after extraction compared to other age groups. However, the control group demonstrated bone loss in all age groups in which the difference is not statistically significant (p-value 0.794). Conclusions: Bone improvements distal to the MSM were observed after the extraction of an IMTM compared to when an IMTM was not extracted. [ABSTRACT FROM AUTHOR]

One of the rare dermatological illnesses that might cause a medical emergency is SJS/TEN. SJS/TEN trigger an aggressive immune reaction to destroy the epithelium of the skin and mucous membranes. They are life-threatening mucocutaneous responses with death rates as high as 30% and a wide range of acute and chronic morbidities. Therefore, early detection and adequate and early treatment can save the patient's life. To review the evaluation of SJS/TEN clinical manifestations and the different aspects of the management. PubMed database search engine was the preferred method for data selection, and the following keys were used in the mesh (("Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis"[Mesh]) AND ("evaluation"[Mesh]) OR ("management"[Mesh])). While there is no test or set of criteria that can determine whether or not an individual has Steven-Johnson syndrome or Toxic epidermal Necrolysis, a skin biopsy can assist in determining other illnesses that have clinical manifestations. Provided there is no effective approach to treat SJS/TEN, presently the best approach is to have a great doubt for the syndrome, early clinical diagnosis, immediate discontinuation of suspected causing substance, supportive therapy, and close monitoring for and treatment of high morbidity complications like infection and ophthalmologic sequelae. Moreover, pain control is crucial to retain a sense of the mental and physical wellbeing of the patients. [ABSTRACT FROM AUTHOR]